Description: Harrow Health, Inc., formerly Imprimis Pharmaceuticals, Inc., is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
Home Page: www.harrowinc.com
HROW Technical Analysis
102 Woodmont Boulevard
Nashville,
TN
37205
United States
Phone:
615 733 4730
Officers
| Name | Title |
|---|---|
| Mr. Mark L. Baum J.D. | CEO & Chairman |
| Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA | CFO & Corp. Sec. |
| Dr. Robert J. Kammer D.D.S. | Special Advisor |
| Mr. John P. Saharek MBA | Chief Commercial Officer |
| Mr. David Moufarrège | VP of Technology |
| Jamie Webb | Director of Communications & Investor Relations |
| Dr. Dennis E Saadeh Pharm.D. | Chief of Formulation Strategy |
| Dr. Larry M. Dillaha M.D. | Chief Medical Officer |
| Mr. Andrew Livingston | Chief Innovation Officer |
| Ms. Kim Barratt | Chief Talent Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 287.6519 |
| Price-to-Sales TTM: | 4.0786 |
| IPO Date: | 2007-09-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 182 |